GB1380246A - 3alpha-hydroxy-androstanes and esters thereof - Google Patents

3alpha-hydroxy-androstanes and esters thereof

Info

Publication number
GB1380246A
GB1380246A GB6006470A GB6006470A GB1380246A GB 1380246 A GB1380246 A GB 1380246A GB 6006470 A GB6006470 A GB 6006470A GB 6006470 A GB6006470 A GB 6006470A GB 1380246 A GB1380246 A GB 1380246A
Authority
GB
United Kingdom
Prior art keywords
prepared
products
hydroxy
group
pregnane
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
GB6006470A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Glaxo Laboratories Ltd
Original Assignee
Glaxo Laboratories Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Glaxo Laboratories Ltd filed Critical Glaxo Laboratories Ltd
Priority to GB6006470A priority Critical patent/GB1380246A/en
Priority to DE19712162555 priority patent/DE2162555A1/en
Priority to AU36962/71A priority patent/AU473167B2/en
Priority to BE776791A priority patent/BE776791A/en
Priority to NL7117256A priority patent/NL7117256A/xx
Priority to BE776786A priority patent/BE776786A/en
Priority to IL38376A priority patent/IL38376A/en
Priority to AU36958/71A priority patent/AU473307B2/en
Priority to FR7145225A priority patent/FR2118117B1/fr
Priority to IL7138378A priority patent/IL38378A/en
Priority to DE19712162595 priority patent/DE2162595A1/en
Priority to CA130,275A priority patent/CA988508A/en
Priority to DK614771AA priority patent/DK133682B/en
Priority to CH1837071A priority patent/CH616691A5/en
Priority to FR7145231A priority patent/FR2118123B1/fr
Priority to ZA718466A priority patent/ZA718466B/en
Priority to DK14674A priority patent/DK135315B/en
Priority to US05/443,451 priority patent/US3953429A/en
Publication of GB1380246A publication Critical patent/GB1380246A/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J1/00Normal steroids containing carbon, hydrogen, halogen or oxygen, not substituted in position 17 beta by a carbon atom, e.g. estrane, androstane
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J17/00Normal steroids containing carbon, hydrogen, halogen or oxygen, having an oxygen-containing hetero ring not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J3/00Normal steroids containing carbon, hydrogen, halogen or oxygen, substituted in position 17 beta by one carbon atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J41/00Normal steroids containing one or more nitrogen atoms not belonging to a hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J43/00Normal steroids having a nitrogen-containing hetero ring spiro-condensed or not condensed with the cyclopenta(a)hydrophenanthrene skeleton
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07JSTEROIDS
    • C07J75/00Processes for the preparation of steroids in general

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Steroid Compounds (AREA)

Abstract

1380246 3α-Hydroxy-androstane compounds and esters thereof GLAXO LABORATORIES Ltd 16 Dec 1971 [17 Dec 1970 (2)] 60064/70 and 60070/70 Headings C2U and C2C Novel 3α-hydroxy-5α-androstanes and 3α- hydroxy-#<SP>4</SP>-androstenes which possess essentially an 11-oxo group, a 17α-hydrogen atom and a 17#-carboxyl, esterified carboxyl, carbamoyl, mono- or di-substituted carbamoyl, cyano, formyl or acetalized formyl group, and which optionally possess further ring double bonds and/or substituents and 3-esters thereof, are prepared (i) when the 17#-substituent R is to be CO 2 H, by oxidation of pregnanes containing 17#-acetyl group; (ii) when R is to be esterified CO 2 H, by esterification of the products of (i); (iii) when R is to be CONH 2 , optionally substituted, by reaction of the products of (i) or derivatives thereof, such as esters and halides, with ammonia or appropriate amines; (iv) when R is to be CHO, by reduction of compounds wherein R is -COhal, or by oxidation of 20,21- dihydroxy-pregnanes; and (v) when R is to be CN, by dehydration of the products of (iii). These products may be esterified in the 3-position, and the 17-formyl compounds may be converted into acetals. #<SP>4</SP>-3α-Ols and their acylates may be prepared by neucleophilic displacement by an OH or O acyl group of an allylically replaceable substituent at the 3#- position. Also, 3α-ols may be prepared by stereospecific reduction of 3-ones; 3α-acyloxy compounds may be prepared by reacting 3#- hydrocarbonsulphonyloxy-5α-androstan-11-ones with carboxylic acids or salts thereof; 3#- alkyl-3α-ols may be prepared by reaction of 3-ones with metal alkyl derivatives; or by reaction of 3-spiro-2<SP>1</SP>-oxiranes with a complex metal hydride (giving 3#-methyl products) or a metal alkyl; products possessing a 2#-substituent, Z may be prepared by re acting 2α,3α-epoxides with a compound ZH furnishing an anion Z-, followed, where a metal derivative of the 3α-ol is first formed, by treatment with a proton source; products having a #<SP>1</SP>-double bond may be prepared by dehydrohalogenation of 2#-halo compounds, with possible protection of the 3α-OH groups as a tetrahydropyranyl ether; products containing an amino substituent in a side chain of an ester may be prepared by esterifying an OH group with an alcohol containing a readily eliminatable substituent such as a halogen atom and then reacting the product with ammonia or an appropriate amine; and 3α-acyloxy products may be hydrolysed to 3α-ols. If an 11-oxo group is reduced in any of these processes it must subsequently be reoxidized. The foregoing processes may also be effected on corresponding pregnanes which are then oxidized as described above. 16α-Alkyl substituents may be insertedinto #<SP>16</SP>-compounds by standard procedures. If protection of the 3α-OH group is needed in any of these processes this may be effected by conversion to an ether or ester, particularly the nitrate ester, with subsequent hydrolysis. Any of the foregoing processes may also be effected on the starting materials and intermediates described below where appropriate. 17#-Halocarbonyl-steroid-starting materials are prepared :from the corresponding 17#-carboxylic acids by standard procedures. 2α,3α-Epoxy-steroid starting materials are prepared by converting 3-ols to their tosylates, converting these to #<SP>2</SP>-steroids and epoxidizing these. 3α,20#,21 - Trihydroxy - 5α - -pregnan - 11 - one is prepared by reduction 3α,21-dihydroxy-5α- pregnene-11,20-dione, prepared in turn by hydrolysis of the 21-acetate. 3# - Hydroxy - 17# - methoxycarbonyl - androst- 4-en-11-one is prepared by reduction of the 3-one, and is subsequently converted to the corresponding 3#-dichloroacetoxy compound. 3α - Hydroxy - 19 - nor - 5α - pregnane -11,20- dione is prepared from 11α, 17α-dihydroxy-19- norpregn-4-ene-3,20-dione via 11α-hydroxy-19- norpregna - 4,16 - diene - 3,20 - dione, 19 - nor- 5α - pregnane - 3,11,20 - trione, and 3#,11α,20#- trihydroxy - 19 - nor - 5α - pregnane. 20,20- Ethylenedioxy-3#-methyl-5α-pregnane-3α-11#-diol is prepared from 5α-pregnane-3,11,20-trione-20- ketal via (3R)-20,20-ethylenedioxy-11-oxo-5α- pregnane-3-spiro-2<SP>1</SP>-oxirane. N - ethyl - N - (2 - hydroxy ethyl) - p - anisidine is prepared from N-ethyl-p-anisidine and ethylene chlorohydrin. The novel 3α-ols (except those containing a free 17#-carboxyl or carbamoyl group) are anaesthetics and may be made up into pharmaceutical compositions with suitable carriers.
GB6006470A 1970-12-17 1970-12-17 3alpha-hydroxy-androstanes and esters thereof Expired GB1380246A (en)

Priority Applications (18)

Application Number Priority Date Filing Date Title
GB6006470A GB1380246A (en) 1970-12-17 1970-12-17 3alpha-hydroxy-androstanes and esters thereof
DE19712162555 DE2162555A1 (en) 1970-12-17 1971-12-16 Anesthetic steroid compounds
AU36962/71A AU473167B2 (en) 1970-12-17 1971-12-16 Anaesthetic steroids
BE776791A BE776791A (en) 1970-12-17 1971-12-16 ANDROSTANE SERIES COMPOUNDS WITH ANESTHESIC ACTIVITY AND THEIR PREPARATION
NL7117256A NL7117256A (en) 1970-12-17 1971-12-16
BE776786A BE776786A (en) 1970-12-17 1971-12-16 PREGNANE AND ANDROSTANE SERIES COMPOUNDS WITH ANESTHESIC ACTIVITY
IL38376A IL38376A (en) 1970-12-17 1971-12-16 3alpha-hydroxy-steroids of the androstane and pregnane series their preparation and pharmaceutical compositions containing them
AU36958/71A AU473307B2 (en) 1970-12-17 1971-12-16 Anaesthetic androstanes
FR7145225A FR2118117B1 (en) 1970-12-17 1971-12-16
IL7138378A IL38378A (en) 1970-12-17 1971-12-16 3 -hydroxy-androstane-17 -carboxylic acid 17 -carboxaldehyde and 17 -carboxamide derivatives and their preparation
DE19712162595 DE2162595A1 (en) 1970-12-17 1971-12-16 Androstane series steroids and process for their manufacture
CA130,275A CA988508A (en) 1970-12-17 1971-12-16 Steroids having useful anaesthetic activity and processes for their preparation
DK614771AA DK133682B (en) 1970-12-17 1971-12-16 Analogous process for the preparation of 3alpha-hydroxy-5alpha-pregn-1-en-20-ones or 3alpha-hydroxy-17beta-alkoxycarbonyl-5alpha-androst-1-ones.
CH1837071A CH616691A5 (en) 1970-12-17 1971-12-16 Process for the preparation of steroid compounds and their use.
FR7145231A FR2118123B1 (en) 1970-12-17 1971-12-16
ZA718466A ZA718466B (en) 1970-12-17 1971-12-17 Improvements in or relating to compounds of the pregnome and adrostane series
DK14674A DK135315B (en) 1970-12-17 1974-01-11 Analogous process for the preparation of anesthetically active 3alpha-hydroxy-11,20-dioxo-5alpha-pregnanes.
US05/443,451 US3953429A (en) 1970-12-17 1974-02-19 Anaesthetic steroids of the androstance and pregnane series

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GB6006470A GB1380246A (en) 1970-12-17 1970-12-17 3alpha-hydroxy-androstanes and esters thereof
GB6007070 1970-12-17

Publications (1)

Publication Number Publication Date
GB1380246A true GB1380246A (en) 1975-01-08

Family

ID=26267810

Family Applications (1)

Application Number Title Priority Date Filing Date
GB6006470A Expired GB1380246A (en) 1970-12-17 1970-12-17 3alpha-hydroxy-androstanes and esters thereof

Country Status (7)

Country Link
AU (1) AU473307B2 (en)
BE (1) BE776791A (en)
DE (1) DE2162595A1 (en)
FR (1) FR2118123B1 (en)
GB (1) GB1380246A (en)
IL (1) IL38378A (en)
NL (1) NL7117256A (en)

Cited By (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591733A (en) * 1987-08-25 1997-01-07 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
WO2018013613A1 (en) * 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
EP3224269A4 (en) * 2014-11-27 2018-07-25 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US10172871B2 (en) 2013-04-17 2019-01-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10323059B2 (en) 2013-07-19 2019-06-18 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10329320B2 (en) 2015-02-20 2019-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
WO2019126761A1 (en) * 2017-12-22 2019-06-27 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US10377790B2 (en) 2013-04-17 2019-08-13 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
US10391106B2 (en) 2013-04-17 2019-08-27 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
US10426837B2 (en) 2015-01-26 2019-10-01 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US10435431B2 (en) 2011-10-14 2019-10-08 Sage Therapeutics, Inc. 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
US10577390B2 (en) 2014-10-16 2020-03-03 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US10822370B2 (en) 2013-04-17 2020-11-03 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
US10870677B2 (en) 2014-10-16 2020-12-22 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US11498940B2 (en) 2013-08-23 2022-11-15 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US11643434B2 (en) 2019-05-31 2023-05-09 Sage Therapeutics, Inc. Neuroactive steroids and compositions thereof

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1434919A (en) * 1972-06-15 1976-05-12 Glaxo Lab Ltd 3alpha-hydroxy androstanes

Cited By (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5591733A (en) * 1987-08-25 1997-01-07 University Of Southern California Methods, compositions, and compounds for allosteric modulation of the gaba receptor by members of the androstane and pregnane series
US10435431B2 (en) 2011-10-14 2019-10-08 Sage Therapeutics, Inc. 3,3 disubstituted 19-nor pregnane compounds, compositions, and uses thereof
US10391106B2 (en) 2013-04-17 2019-08-27 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
US11912737B2 (en) 2013-04-17 2024-02-27 Sage Therpeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
US10822370B2 (en) 2013-04-17 2020-11-03 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
US10172871B2 (en) 2013-04-17 2019-01-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
US11241446B2 (en) 2013-04-17 2022-02-08 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
US11261211B2 (en) 2013-04-17 2022-03-01 Sage Therapeutics, Inc. 19-NOR neuroactive steroids and methods of use thereof
US10342810B2 (en) 2013-04-17 2019-07-09 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-N-pyrazolyl steroids and methods of use thereof
US11344563B2 (en) 2013-04-17 2022-05-31 Sage Therapeutics, Inc. 19-nor C3, 3-disubstituted C21-C-bound heteroaryl steroids and methods of use thereof
US10377790B2 (en) 2013-04-17 2019-08-13 Sage Therapeutics, Inc. 19-nor neuroactive steroids and methods of use thereof
US10323059B2 (en) 2013-07-19 2019-06-18 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US11046728B2 (en) 2013-07-19 2021-06-29 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US11498940B2 (en) 2013-08-23 2022-11-15 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10745436B2 (en) 2014-06-18 2020-08-18 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US10246482B2 (en) 2014-06-18 2019-04-02 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US11780875B2 (en) 2014-06-18 2023-10-10 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US11530237B2 (en) 2014-10-16 2022-12-20 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US10577390B2 (en) 2014-10-16 2020-03-03 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US11542297B2 (en) 2014-10-16 2023-01-03 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US10870677B2 (en) 2014-10-16 2020-12-22 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
EP3719029A1 (en) * 2014-11-27 2020-10-07 Sage Therapeutics, Inc. Compositions for inducing sedation
US11945836B2 (en) 2014-11-27 2024-04-02 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US10774108B2 (en) 2014-11-27 2020-09-15 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
EP3224269A4 (en) * 2014-11-27 2018-07-25 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
US11147877B2 (en) 2015-01-26 2021-10-19 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US10426837B2 (en) 2015-01-26 2019-10-01 Sage Therapeutics, Inc. Compositions and methods for treating CNS disorders
US10329320B2 (en) 2015-02-20 2019-06-25 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US11124538B2 (en) 2015-02-20 2021-09-21 Sage Therapeutics, Inc. Neuroactive steroids, compositions, and uses thereof
US11396525B2 (en) 2016-07-11 2022-07-26 Sage Therapeutics, Inc. C17, C20, and C21 substituted neuroactive steroids and their methods of use
JP2019520416A (en) * 2016-07-11 2019-07-18 セージ セラピューティクス, インコーポレイテッド C17, C20, and C21 substituted neurostimulatory steroids and methods of using them
WO2018013613A1 (en) * 2016-07-11 2018-01-18 Sage Therapeutics, Inc. C17, c20, and c21 substituted neuroactive steroids and their methods of use
WO2019126761A1 (en) * 2017-12-22 2019-06-27 Sage Therapeutics, Inc. Compositions and methods for treating cns disorders
JP2021506904A (en) * 2017-12-22 2021-02-22 セージ セラピューティクス, インコーポレイテッド Compositions and Methods for the Treatment of CNS Disorders
CN111741965A (en) * 2017-12-22 2020-10-02 萨奇治疗股份有限公司 Compositions and methods for treating central nervous system disorders
US11643434B2 (en) 2019-05-31 2023-05-09 Sage Therapeutics, Inc. Neuroactive steroids and compositions thereof

Also Published As

Publication number Publication date
AU3695871A (en) 1973-06-21
NL7117256A (en) 1972-06-20
IL38378A0 (en) 1972-02-29
AU473307B2 (en) 1976-06-17
DE2162595A1 (en) 1972-07-06
FR2118123B1 (en) 1975-11-28
BE776791A (en) 1972-06-16
FR2118123A1 (en) 1972-07-28
IL38378A (en) 1979-01-31

Similar Documents

Publication Publication Date Title
GB1380246A (en) 3alpha-hydroxy-androstanes and esters thereof
US3943124A (en) Chemical compounds
GB1039441A (en) 2ª‰-amino-3ª‡-hydroxy-5ª‡-steroids and the preparation thereof
GB1472922A (en) Pregnanoic acid derivatives
IL35823A (en) Process for the preparation of 16beta-methyl-9alpha-fluoro-11beta,17alpha,21-trihydroxy-1,4-pregnadiene-3,20-dione and its 21-acylates
US2875200A (en) 9alpha-halo-11beta, 21-dihydroxy-4, 17(20)-pregnadiene-3-one compounds and process of preparing thereof
GB1530615A (en) 15,16-methylene-steroids of the pregnane series
US2905678A (en) 6beta-hydroxy-delta4-pregnenes
US3014936A (en) 15-dehydro-cortical hormones
US3014030A (en) 9alpha-methylpregnenes, pregnadienes and intermediates therefor
US3072644A (en) 20, 21-ketols of the pregnane series and process for their manufacture
IE36592B1 (en) Process for the manufacture of pregnane derivatives
GB1380248A (en) 3alpha-hydroxy steroids and esters thereof
US3155695A (en) 16-difluoromethyl adrenocorticoids
GB1051693A (en)
US3072645A (en) 17alpha:21-dihydroxy-20-ketones of the pregnane series and process for their manufacture
US2870141A (en) 6-fluoro-20-hydroxy-4-pregnen-3-ones and the 20-acylates thereof
US2923722A (en) 2-lower-alkyl-9alpha-halo-4-pregnenes
US3223717A (en) 16-fluoromethyl pregnene derivatives
US3092626A (en) Process for the manufacture of 16-alkyl-20:21-ketols of the pregnane series
US3257434A (en) 16-methyl-15-dehydro-corticoids
US3047570A (en) C-12-substituted progesterone
US3018284A (en) 16, 17-oxido-allopregnane-3, 20-dionederivatives
US2773887A (en) Pregnane-11alpha, 17alpha-diol-3, 20-diones, esters thereof and process
US2786836A (en) Compounds for synthesizing steroids

Legal Events

Date Code Title Description
PS Patent sealed [section 19, patents act 1949]
PCNP Patent ceased through non-payment of renewal fee